Search research articles
Contact Us
Filters
Showing results (101-110 of 241) with videos related to
Page
of 25
Sort By:
Cell
|
June 18, 2016
Engineered Bispecific Antibodies with Exquisite HIV-1-Neutralizing Activity
Yaoxing Huang, Jian Yu, Anastasia Lanzi, et al.
The Journal of Infectious Diseases
|
March 28, 2003
Determining the relative efficacy of highly active antiretroviral therapy
Michael Louie, Christine Hogan, Michele Di Mascio, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
January 25, 2005
Bacterial glycolipids and analogs as antigens for CD1d-restricted NKT cells
Douglass Wu, Guo-Wen Xing, Michael A Poles, et al.
JAMA Internal Medicine
|
April 22, 2021
SARS-CoV-2 Transmission Risk Among National Basketball Association Players, Staff, and Vendors Exposed to Individuals With Positive Test Results After COVID-19 Recovery During the 2020 Regular and Postseason
Christina D Mack, John DiFiori, Caroline G Tai, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
July 16, 2020
Quantifying the contribution of Fc-mediated effector functions to the antiviral activity of anti-HIV-1 IgG1 antibodies in vivo
Pengfei Wang, Mili R Gajjar, Jian Yu, et al.
Nature Communications
|
April 2, 2021
Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors
Sho Iketani, Farhad Forouhar, Hengrui Liu, et al.
The Lancet. Infectious Diseases
|
February 7, 2025
KP.2-based monovalent mRNA vaccines robustly boost antibody responses to SARS-CoV-2
Qian Wang, Ian A Mellis, Madeline Wu, et al.
Iscience
|
November 29, 2023
Evolving antibody evasion and receptor affinity of the Omicron BA.2.75 sublineage of SARS-CoV-2
Qian Wang, Zhiteng Li, Yicheng Guo, et al.
Nature Communications
|
May 6, 2021
Author Correction: Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors
Sho Iketani, Farhad Forouhar, Hengrui Liu, et al.
Journal of Virology
|
February 23, 2007
Natural mutations in the receptor binding domain of spike glycoprotein determine the reactivity of cross-neutralization between palm civet coronavirus and severe acute respiratory syndrome coronavirus
Li Liu, Qing Fang, Fei Deng, et al.
Page
of 25
Search research articles
Search
Showing results (101-110 of 241) with videos related to
Sort By:
Page
of 25
Cell
|
June 18, 2016
Engineered Bispecific Antibodies with Exquisite HIV-1-Neutralizing Activity
Yaoxing Huang, Jian Yu, Anastasia Lanzi, et al.
The Journal of Infectious Diseases
|
March 28, 2003
Determining the relative efficacy of highly active antiretroviral therapy
Michael Louie, Christine Hogan, Michele Di Mascio, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
January 25, 2005
Bacterial glycolipids and analogs as antigens for CD1d-restricted NKT cells
Douglass Wu, Guo-Wen Xing, Michael A Poles, et al.
JAMA Internal Medicine
|
April 22, 2021
SARS-CoV-2 Transmission Risk Among National Basketball Association Players, Staff, and Vendors Exposed to Individuals With Positive Test Results After COVID-19 Recovery During the 2020 Regular and Postseason
Christina D Mack, John DiFiori, Caroline G Tai, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
July 16, 2020
Quantifying the contribution of Fc-mediated effector functions to the antiviral activity of anti-HIV-1 IgG1 antibodies in vivo
Pengfei Wang, Mili R Gajjar, Jian Yu, et al.
Nature Communications
|
April 2, 2021
Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors
Sho Iketani, Farhad Forouhar, Hengrui Liu, et al.
The Lancet. Infectious Diseases
|
February 7, 2025
KP.2-based monovalent mRNA vaccines robustly boost antibody responses to SARS-CoV-2
Qian Wang, Ian A Mellis, Madeline Wu, et al.
Iscience
|
November 29, 2023
Evolving antibody evasion and receptor affinity of the Omicron BA.2.75 sublineage of SARS-CoV-2
Qian Wang, Zhiteng Li, Yicheng Guo, et al.
Nature Communications
|
May 6, 2021
Author Correction: Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors
Sho Iketani, Farhad Forouhar, Hengrui Liu, et al.
Journal of Virology
|
February 23, 2007
Natural mutations in the receptor binding domain of spike glycoprotein determine the reactivity of cross-neutralization between palm civet coronavirus and severe acute respiratory syndrome coronavirus
Li Liu, Qing Fang, Fei Deng, et al.
Page
of 25